At this stage, the GO@peg4‐KLVFF system has been demonstrated to be promising for the development of future AD diagnostics devices, due to the following remarkable properties: a great ability to detect Aβ42 monomers; the selectivity toward Aβ42 (the system responds specifically only in the presence of Aβ42, and not in the presence of scrambled structures containing the same amino acids arranged in a random order) or the other AD‐related Tau 26–44; an extremely fast response thanks to the interaction between the GO@peg4‐KLVFF system and the Aβ42, that occurs within a few minutes. The gene discussed is MAPT; the disease is Alzheimer disease.